A Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Next Previous
Trial Profile

A Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Telomelysin (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Oncolys BioPharma

    • Most Recent Events

    • 18 Nov 2014 The first patient has been enrolled, according to an Oncolys BioPharma media release.
    • 18 Nov 2014 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
    • 30 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top